SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-101292
Filing Date
2024-04-19
Accepted
2024-04-18 21:46:30
Documents
15
Period of Report
2024-04-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d826079d8k.htm   iXBRL 8-K 26792
2 EX-99.1 d826079dex991.htm EX-99.1 17257
6 GRAPHIC g826079g0419042308105.jpg GRAPHIC 14216
  Complete submission text file 0001193125-24-101292.txt   196708

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20240418.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20240418_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20240418_pre.xml EX-101.PRE 11712
18 EXTRACTED XBRL INSTANCE DOCUMENT d826079d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 24855473
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)